rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
1993-1-14
|
pubmed:abstractText |
Approximately one third of the patients with superficially infiltrative transitional cell (T1-TNM pathological staging system) bladder carcinoma who are treated with transurethral resection alone have disease progression. Despite precise pathologic staging and grading, clinical outcome in these patients is not predictable. Recent reports reveal that mutations of the p53 tumor suppressor gene (also known as TP53) occur commonly in bladder cancers.
|
pubmed:grant |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0027-8874
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
6
|
pubmed:volume |
85
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
53-9
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:7677935-Adult,
pubmed-meshheading:7677935-Aged,
pubmed-meshheading:7677935-Aged, 80 and over,
pubmed-meshheading:7677935-Analysis of Variance,
pubmed-meshheading:7677935-Carcinoma, Transitional Cell,
pubmed-meshheading:7677935-Carcinoma in Situ,
pubmed-meshheading:7677935-Female,
pubmed-meshheading:7677935-Genes, p53,
pubmed-meshheading:7677935-Humans,
pubmed-meshheading:7677935-Immunoenzyme Techniques,
pubmed-meshheading:7677935-Male,
pubmed-meshheading:7677935-Middle Aged,
pubmed-meshheading:7677935-Multivariate Analysis,
pubmed-meshheading:7677935-Mutation,
pubmed-meshheading:7677935-Neoplasm Proteins,
pubmed-meshheading:7677935-Neoplasm Staging,
pubmed-meshheading:7677935-Neovascularization, Pathologic,
pubmed-meshheading:7677935-Prognosis,
pubmed-meshheading:7677935-Retrospective Studies,
pubmed-meshheading:7677935-Survival Analysis,
pubmed-meshheading:7677935-Tumor Markers, Biological,
pubmed-meshheading:7677935-Tumor Suppressor Protein p53,
pubmed-meshheading:7677935-Urinary Bladder Neoplasms
|
pubmed:year |
1993
|
pubmed:articleTitle |
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
|
pubmed:affiliation |
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, N.Y. 10021.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|